Sanofi records solid growth in Q2 with net sales  Euro 8,628 million

KUALA LUMPUR, July 29 (Bernama) -- Sanofi has delivered solid growth in Q2 2019 driven by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets with net sales of €8,628 million, an increase of 5.5 per cent on a reported basis. (€1 = RM4.59)

The company has reported that Sanofi Genzyme sales were up 21.8 per cent due to the strong launch performance of Dupixent®, while vaccine sales increased 24.7 per cent, mainly reflecting the recovery and growth of Pentaxim® in China and low basis for comparison.

Its business net income in the same quarter also recorded an increase of 5.3 per cent to €1,641 million, according to a statement.

“Our increased focus in R&D delivered important results with several positive data read-outs and the achievement of regulatory milestones,” said Sanofi chief executive officer, Olivier Brandicourt.

“We are confident in the growth outlook for the year. Consequently, we have revised upward our guidance for full-year business EPS growth to approximately five per cent.”

Sanofi has also achieved several key regulatory milestones in R&D, including Isatuximab accepted for review by the FDA and EMA for approval in relapsed/refractory multiple myeloma and Libtayo® approved for advanced cutaneous squamous cell carcinoma in the EU.

The company has also collaborated with Google to establish a new virtual Innovation Lab, aiming to transform how future medicines and health services are delivered by tapping into the power of emerging data technologies.

For more information, contact https://www.sanofi.com.

-- BERNAMA